Observational Study to Evaluate the Safety of Levemir® in Diabetes
Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
This study is conducted in Africa, Asia, Europe, Japan and South America. The aim of this
observational study is to evaluate the incidence of serious adverse reactions (SARs) while
using Levemir® (insulin detemir) under normal clinical practice conditions.
Study conducted globally in 26 countries. Some countries participated in the study for only 3
months (Austria, Brazil, Denmark, Germany, Israel, Lebanon, Slovenia, Russia, and Turkey),
while others extended their participation to 6 (Belgium/Luxembourg, Czech Republic, Greece,
India, Italy, Netherlands, Saudi Arabia, South Africa, South Korea, Sweden, Tunisia, and
United Kingdom/Ireland) and 12 months (Finland, France, and Japan), respectively.